Thetis Pharmaceuticals Receives $1.9 Million Fast-Track NIH

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
400
Thetis Pharmaceuticals Receives $1.9 Million Fast-Track NIH Grant to Advance Novel Inflammatory Bowel Disease Drug Pipeline Toward Clinical Investigation

BRANFORD, Conn., May 23, 2018 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals, a biopharmaceutical company developing novel therapies for treatment of inflammatory bowel disease (IBD), today announced the receipt of a Fast-Track Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH). The award provides up to $1.9 million to support development of Thetis’ TP-252 drug candidate as oral therapy for ulcerative colitis, a chronic, relapsing inflammatory gastrointestinal disorder affecting 800,000 patients in the U.S. and nearly 5 million worldwide.

Gary Mathias, co-founder and Chief Executive Officer, commented: “TP-252 is a novel patented molecule that delivers a natural lipid that has been shown in an independent Phase 2 study to reduce relapse rates and inflammatory biomarkers in ulcerative colitis patients. Based on this compelling clinical proof-of-concept data and the anticipated benign safety profile of our molecule, we are in discussions with potential partners to begin clinical investigation in 2019.”

Dr. Brian E. Harvey, Thetis’ Senior Medical Director and former Director of the Division of Gastroenterology Products at the FDA, commented, “There is a high unmet medical need for safe, oral therapies that can be used with first-line therapy to help patients maintain remission, thereby reducing the need for aggressive immunosuppressive agents. TP-252 offers a benefit-risk profile that is ideally suited for patients with a history of mild-to-moderate disease seeking a safe agent to help reduce the risk of relapse.”

About TP-252 TP-252 is being developed as adjunct therapy to 5-ASA for maintenance of remission in ulcerative colitis patients. This positioning is based on recent clinical evidence from a randomized, placebo-controlled, double-blind Phase 2 trial showing that oral administration of the active moiety in TP-252 significantly reduces the rate of relapse in UC patients already on therapy (see Scaioli et al. 2018). TP-252 has composition of matter patent protection in the U.S., notice of allowance for patent issuance in Europe, and additional applications pending in other major global markets.

About Thetis Thetis Pharmaceuticals is a biopharmaceutical company developing novel therapies for the treatment of IBD and other inflammatory diseases. Thetis’ proprietary technology platform enables the pharmaceutical development of bioactive lipids that actively regulate inflammation and promote tissue repair and healing. Thetis’s technology overcomes the stability, manufacturing, formulation and patentability hurdles that have limited the development of bioactive lipids as pharmaceutical agents, unlocking their robust pharmacology to be developed as first-in-class therapeutics. During the last 9 months, Thetis has received two Fast Track SBIR awards providing over $4 million to fund development of its unique IBD pipeline.

Thetis is funded by Connecticut Innovations, Inc. and is a member of the Technology Incubation Program at University of Connecticut Health. Preclinical efficacy studies funded under the grant (1R44DK116463) are being conducted in collaboration with Dr. Daniel Rosenberg, Professor of Medicine at the University of Connecticut.

For more information, please visit Thetis’ website (www.thetispharma.com) and follow Thetis on Twitter (@thetispharma).

Contact Information Aaron Mathias Director Business Development amathias@thetispharma.com

Disclaimer The SBIR Award (R44DK116463) is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. Statements regarding TP-252 and the SBIR Award are solely the responsibility of Thetis Pharmaceuticals LLC and do not represent the official views of the National Institutes of Health.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 348

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

DEWALT Invests $4 Million in Future Trades Professionals

Updated Category News Views 104

DEWALT Invests Substantially in Skills Development In a notable effort to strengthen the future of skilled trades, DEWALT has revealed plans to allocate nearly $4 million in Grow the Trades grants to 166 organizations dedicated to training, retraining, and enhancing the skills of tradespeople across the U.S. and Canada. This initiative forms part of a broader commitment...

Continue Reading
Fairfax Financial Reports Spectacular Q3 Earnings Boost

Updated Category News Views 152

Fairfax Financial Holdings Limited Financial Results Overview Fairfax Financial Holdings Limited (TSX: FFH) recently shared its financial results for the third quarter, showcasing a robust increase in net earnings and strong operational performance. The results for this period underscore the company's commitment to growth, stability, and strategic acquisitions, focusing...

Continue Reading
U.S. Postal Service Board Meeting: Open to Public Attendance

Updated Category News Views 195

U.S. Postal Service Board of Governors Meeting Overview The U.S. Postal Service Board of Governors is set to convene for an important session that invites public observation. This meeting, hosted at the headquarters, is an opportunity for community engagement and transparency into the board's activities. Meeting Details and Agenda The open session is scheduled to begin in...

Continue Reading
Franklin Financial Revamps Portfolio and Keeps Dividend Steady

Updated Category News Views 198

Franklin Financial Restructures Its Investment Portfolio Franklin Financial Services Corp (NASDAQ:FRAF), the parent company of Farmers and Merchants Trust Company, has recently executed a notable reshuffling of its investment portfolio. The firm initiated the sale of approximately $46.7 million in lower-yielding U.S. Treasury securities, leading to an estimated after-tax...

Continue Reading
Discovering the Remarkable Growth of Sterling Infrastructure

Updated Category News Views 163

Understanding Sterling Infrastructure's Growth Over Time Sterling Infrastructure (NASDAQ: STRL) has consistently outperformed the market over the past decade. With an impressive annualized growth rate of 42.7%, this company has provided its investors with remarkable returns, boasting an average annual return of 55.14%. Presently, Sterling Infrastructure enjoys a robust...

Continue Reading